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Background: Recognizing of factors involved in the ces-
sation and interruption of a disease like tuberculosis are
important and can help us to improve the treatment strat-
egy and educational status of the patients. We assessed the
causes of treatment cessation in the patients suffering from
pulmonary tuberculosis referred to the tuberculosis Center
No.2 in Khorasan Province of Iran during the years March
2003 to March 2005.
Methods: A descriptive and retrospective study of case-
sheets of all pulmonary tuberculosis’ patients who were
referred to the Mashhad Health Center No. 2 during the years
2003 to 2005 and the variables like age, sex, nationality, out-
come of treatment and causes of treatment cessation and
interruption were presented with descriptive statistic.
Results: The total number of the patients were 659.
Of these patients, 534 (81%) were smear positive and 125
(19%) were smear negative. Among the 534 smear-positive
patients, 43 (8%) have treatment cessation and interrup-
tion. The reasons of treatment interruption were mortality
due to T.B in 20 patients (3.7%), drug induced hepatitis
in 11 (2%), premature sensation of wellbeing in 2 (0.37%),
Hearing problems and vertigo in 2 (0.37%), multi drug
resistance (MDR) tuberculosis, in 2 (0.37%), purpura in 1
(0.2%), and exacerbation of renal failure in 2 (0.37%). 438
cases (82%) had total cure.
Conclusion: Observation supported the effectiveness of
directly observed therapy short course (DOTS) strategy, with
ﬁrst line therapy. The causes of treatment cessation and
interruption like drugs’ induced hepatitis and premature
sensation of wellbeing can be controlled by increasing the
awareness of patients about the severity of T.B disease.
Efforts to improve patients’ understanding of TB disease
and related treatment issues may be an important TB
control program strategy and should be emphasized at
the initiation of therapy and at intervals throughout the
treatment course to minimize treatment interruption.
doi:10.1016/j.ijid.2008.05.677
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A 15-year-old boy presented to the Orthopaedic Depart-
ment for neck, thoracic and back pain for 6 weeks. The pain
progressively worsened and caused difﬁculty in walking and
sitting. His had signiﬁcant constitutional upset. Examination
revealed tenderness and decreased range of movement over
the lower cervical spine region and thoraco-lumbar junction.
There was no motor or sensory deﬁcit. MRI of the cervical
and thoracic spine showed erosion of the anterior vertebral
body from C5 to T1 level with paraspinal soft tissue swelling
from C4 to T1 level which was compatible with tuberculous
spondylitis. Imaging also showed extensive involvement of
the thoracic and lumbar spines with paraspinal soft tissue
involvement and left psoas abscess formation. Blood tests
revealed hypochromic microcytic anaemia, raised ESR and
CRP. He was empirically treated with standard antitubercu-
lous drugs. Anterior spinal fusion of C7 to T1 level was per-
formed. Despite treatment he had persistent swinging fever.
A second operation was performed which consisted of tho-
racotomy and drainage of the abscessed at T7 and the left
psoas. Central line was also inserted for administration of
drugs and TPN. Pus and granulation tissue collected yielded
large number of AFB and PCR was positive for Mycobac-
terium tuberculosis (MTB) complex. Formal susceptibility
testing of the MTB isolate later conﬁrmed multi-drug resis-
tant tuberculosis with resistance to isoniazid, rifampicin,
streptomycin and ethambutol while susceptibility testing
showed sensitivity to most agents except oﬂoxacin. Immune
function screening showed normal ﬁndings. He was HIV
negative. The treatment was change to levoﬂoxacin, pro-
thionamide, para-aminosalicylic acid, cycloserine, linezolid
and amikacin. In conclusion, tuberculous spondylitis should
be considered in any patient who presented with neck pain,
back pain and constitutional upset. Prompt isolation of the
AFB with susceptibility test for detection of drug resistance
is vital to the clinical management. Immune function disor-
der should be considered in individual case.
doi:10.1016/j.ijid.2008.05.678
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Background: MDR-TB imposes a formidable burden on
countries health systems. There is not still a consensus on
the subject and there are controversies regarding treatment
protocols, treatment outcomes and various regimens.
Methods: This study accounts for Iran’s Second National
Cohort for treatment of MDR-TB. The study comprises all
MDR TB documented cases in Iran referred to our cen-
ter during the period of 2002—2006. All patients received
standardized second-line regimen uniformly consisted of
Oﬂoxacin, Cycloserine, Prothionamide and Amikacin. Based
on drug susceptibility tests Ethambutol and Pyrazinamide
were added to the regimen.
Results: Finally, 43 patients with diagnosis of MDR-TB
were involved for treatment, among those 27 (62.8%) were
male. Mean age was 44.38± 19.05. Twenty three (53.5%)
of them were Iranians and the remaining were Afghan.
All patients were secondary MDR-TB cases. Of total 43
cases, 25(58.1%) experienced major and clinically signiﬁcant
adverse effects. 29(67.5%) had successful outcome. Con-
versely, overall 14 (32.5%) showed poor outcome {Treatment
Failure in 6(14%) and Death in 8(18.6%)}. Mortality was
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higher in Iranians (P-value: 0.039) and in patients whose
initial regimen was changed due to adverse drug reaction.
(P-value: 0.01) Conclusion: MDR-TB treatment using stan-
dardized regimen showed favorable outcome in our study,
comparing with previous studies.
doi:10.1016/j.ijid.2008.05.679
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Background: The only treatment available for severe
leprosy Type 1 Reactions (T1R) is prednisolone but a sig-
niﬁcant number of patients do not respond to treatment.
There have been 2 case reports of successful treatment
of non-responsive T1R with cyclosporin A (CyA). This
study uses an Indian microemulsion formulation of CyA
(Panimmune) as monotherapy to treat patients with severe
T1R. Evidence is now available showing that some ethnic
groups metabolise CyA differently. Genetic differences
have also been identiﬁed in the genes responsible for CyA
metabolism (cytochrome P450) in various ethnic groups.
It is important to identify any groups that metabolize or
absorb CyA differently as this will help in deciding the
optimal dose to be used.
Aims: To identify any differences in dose requirements for
CyA treatment of severe leprosy T1Rs in the 2 racial groups
and whether these differences were related to genetic vari-
ations.
Methods: 33 Ethiopian and 12 Nepali patients with severe
T1Rs were recruited and treated with CyA at a dose of
5—10mg/kg/day; dose increases were dependent on clini-
cal improvement. Trough blood concentrations of CyA were
analysed using a Liquid Chromotography/Tandem Mass Spec-
trometry assay. Pharmacokinetic studies were carried out on
a subgroup of patients. DNA was extracted from whole blood
and samples genotyped using PCR and restriction length
polymorphism (RFLP). For CYPA5, AA, AG and GG genotypes
were identiﬁed and for MDR1, CC, CT and TT genotypes were
identiﬁed.
Results: 77% Ethiopian patients needed a higher dose
of CyA than the Nepalis to show a clinical improvement.
Patients with the TT and GG genotypes achieved a higher
Cmax and area under the curve (AUC) for CyA than those
with CC/CT or AG/AA genotypes respectively.
Conclusion: Polymorphisms in CYP3A5 and MDR1 may
explain variation in dose requirements for CyA in different
racial groups. This is important for all drugs that are hepat-
ically metabolised and in particular HAART medication.
doi:10.1016/j.ijid.2008.05.680
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Background: Since the use of new adjuvants in design-
ing new vaccines against most of infectious diseases should
be improved, many candidates are recommended for mod-
ulating an immune response to an antigen. Neisseria
meningitidis serogroup B outer membrane vesicle (OMV) has
been used previously by Siadat et al (2007), as a carrier for
polysaccharide immunogens. In this study OMV used as an
adjuvant for group A meningococcal capsular polysaccha-
ride (GAMP) and was tested in Newzeland white rabbit for
bactericidal antibody activity induction.
Methods: The complex of OMV with GAMP, in no covalent
form, and control were injected intramuscularly into groups
of four rabbits with boosters on day 14 and 28 after primary
immunization. The following groups were used as control:
1.GAMP, 2.OMV and 3.normal saline. The serum samples
collected on days 0, 14, 28 and 42 and tested by comple-
ment mediated bactericidal assay against serogroup A and
B meningococci according to the world health organization
protocol.
Results: Rabbits given three dose of the complex of
serogroup B meningococcal OMV with GAMP developed high
level of serum bactericidal activity against serogroup A
meningococci after 42 days in comparison with the GAMP
and OMV control group (P < 0.005). Bactericidal titer against
serogroup B meningococci of the GAMP plus OMV complex
showed no signiﬁcant difference in comparison with the OMV
containing control (P > 0.005).
Conclusion: The results indicate that the combination of
OMV with GAMP, in non covalent form, would be able to
induce a high level of bactericidal antibody response in com-
parison with GAMP. The OMV of Neisseria meningitidis is a
potent protein carrier in the induction of immune system
but in this article the role of OMV is studied as an immune
system promotor in non-covalent form and without any con-
jugation process(as an adjuvant) in order to induce immune
response against three prevalent serogroups of Neisseria
meningitidis.
doi:10.1016/j.ijid.2008.05.681
